P16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology

Cancer Cytopathology

Volumn 119, Issue 3, 2011, Pages 158-166

  Schmidt, Dietmar ^b   Bergeron, Christine ^c   Denton, Karin J ^d   Ridder, Ruediger ^a  

^a MTM Laboratories AG   (Germany)

^b Institute of Pathology   (Germany)

^c LABORATOIRE CERBA   (France)

^d NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

ASCUS; Cervical intraepithelial neoplasia; CIN; Dual stain cytology; HPV; Human papillomavirus; Ki 67; LSIL; P16INK4a

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; P16 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; ADOLESCENT; EUROPE; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY; VAGINA SMEAR;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; EUROPE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VAGINAL SMEARS; YOUNG ADULT;

EID: 80051606647     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20140     Document Type: Article

References (21)

1. Guo M, Hu L, Baliga M, HE Z, Hughson MD. The predictive value of p16INK4a and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2004;122:894-901.
2. Trunk MJ, Dallenbach-Hellweg G, Ridder R, et al. Morphologic characteristics of p16INK4a-positive cells in cervical cytology samples. Acta Cytol. 2004;48:771-782.
3. Holladay EB, Logan S, Arnold J, Knesel B, Smith GD. A comparison of the clinical utility of p16INK4a immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer Cytopathol. 2006;108:451-461.
4. Meyer JL, Hanlon DW, Andersen BT, Rasmussen OF, Bisgaard K. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16 INK4a assay. Cancer Cytopathol. 2007;111:83-92.
5. Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M. Triage of women with ASCUS and LSIL cytology. Use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer Cytopathol. 2007;111:58-66.
6. Schlederman D, Andersen BT, Bisgaard K, et al. Are adjunctive markers useful in routine cervical cancer screening? Application of p16INK4a and HPV-PCR on ThinPrep samples with histological follow-up. Diagn Cytopathol. 2008;36:453-459.
7. Denton KJ, Bergeron C, Klement P, et al. The sensitivity and specificity of p16INK4a cytology vs. HPV testing for detecting high-grade cervical disease in the triage of ASCUS and LSIL Pap cytology results. Am J Clin Pathol. 2010;134:12-21.
8. Samarawardana P, Dehn DL, Singh M, et al. p16INK4a is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia. Cancer Cytopathol. 2010;118:146-156.
9. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev;. 2008;17:2536-2545.
10. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysis. Cancer Treatment Rev. 2009;35:210-220.
11. Stoler MH. Toward objective cervical cancer screening. Maybe the eyes do have it [editorial]. Am J Clin Pathol. 2010;134:5-6.
12. Wright JD, Rader JS, Davila R, et al. Human papillomavirus triage for young women with atypical squamous cells of undetermined significance. Obstet Gynecol. 2006;107:822-829.
13. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
14. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections, Eur J Cancer. 2002;38: 2229-2242.
15. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system. Terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-219.
16. Longatto Filho A, Utagawa ML, Shirata NK, et al. Immunocytochemical expression of p16INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus. Int J Gynecol Pathol. 2005;24:118-124.
17. Sahebali S, Depuydt CE, Boulet GA, et al. Immunocytochemistry in liquid-based cervical cytology: Analysis of clinical use following a cross-sectional study. Int J Cancer. 2006;118:1254-1260.
18. Goel MM, Mehrotra A, Singh U, et al. MIB-1 and PCNA immunostaining as a diagnostic adjunct to cervical Pap smear. Diagn Cytopathol. 2005;33:15-19.
19. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
20. Solomon D, Schiffman M, Tarone R. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
21. Arbyn M, Martin-Hirsch P, Buntinx F, et al. Triage of women with equivocal or low-grade cervical cytology results: A meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009;13:648-659.